Cargando…
Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
BACKGROUND: The nonvitamin K antagonist oral anticoagulants pivotal clinical trials for stroke prevention in atrial fibrillation have important differences in trial designs and baseline patient characteristics. OBJECTIVE: We sought to evaluate the relative efficacy and safety of edoxaban versus othe...
Autores principales: | Fernandez, Maria M, Wang, Jianmin, Ye, Xin, Kwong, Winghan Jacqueline, Sherif, Bintu, Hogue, Susan, Sherrill, Beth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822531/ https://www.ncbi.nlm.nih.gov/pubmed/27092254 http://dx.doi.org/10.1177/2050312115613350 |
Ejemplares similares
-
Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015) -
Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
por: Kim, Jong S.
Publicado: (2019) -
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015) -
The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021) -
Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)